Amarin Corp Plc (AMRN)

[jomama9231]

Correct and Many on this board are missing this very important point. Generics are only interested in getting the marine label for reduction of TG > 500. In getting that label they’ll essentially win the full market of marine and reduce it by inducing infringement but that needs to be argued after. They’re trying to bust a patent that basically is saying the lowering of apo B in pts on Vascepa with TG > 500 was obvious and therefore they don’t infringe etc. All literature should be strictly related to the biomarkers and has nothing to do with how suprised people were with reduce it results. Furthermore, I am not even sure what can be legally argued from adding reduce it to the trial. What would be amrns argument as it relates to the obviousness bc none of the reduce it pts had TG > 500 so does it even apply ?

I’d love to see amrn expert testimony but I think it’s sealed.